Mass Spectrometry, HPLC, and LAL Endotoxin Testing

No single analytical method describes a research peptide batch completely. Three methods together — mass spectrometry for identity, HPLC for purity, and LAL (or rFC) for endotoxin contamination — answer three different questions about the material, and a complete batch release requires all three. This article explains what each method physically measures, what it cannot tell you, and why the combination is non-substitutable.

The three methods form the spine of every reputable research peptide Certificate of Analysis. The field-by-field COA walkthrough shows how each result is reported on the document; the ≥99% purity threshold cornerstone goes deeper on the HPLC side specifically. Lyophilization is what makes the tested batch shelf-stable from analysis to receipt — covered in the lyophilization and reconstitution primer — and cold-chain handling is what preserves it in transit.

What three questions does the framework answer?

Each method answers exactly one question that the others cannot. The questions don't overlap, and a result on one method does not substitute for a result on another. The table below makes the non-substitutability concrete.

A 99.9%-pure batch of the wrong peptide is HPLC-clean but identity-failed. A correctly-identified batch with 5% impurities is identity-confirmed but purity-failed. A pure, identified batch with high endotoxin is HPLC-clean and identity-confirmed but contaminated for any research application sensitive to LPS. All three results together describe a batch sufficient for release; any one result alone does not.

How does mass spectrometry confirm identity?

Mass spectrometry ionizes a sample, separates the resulting ions by their mass-to-charge ratio (m/z), and counts how many ions of each m/z reach the detector. For peptide identification, the standard ionization method is electrospray ionization (ESI), which produces multiply-charged ions of the intact peptide. The detector returns a spectrum showing the dominant charge states.

The peptide's theoretical molecular weight is calculated directly from its amino acid sequence — every residue has a known monoisotopic mass, and the full peptide mass is the sum of its residues plus a water of hydrolysis correction at the termini. The observed mass from the spectrometer is compared to the theoretical value. If they match within the instrument's accuracy — typically within ±0.5 daltons for low-resolution instruments, sub-dalton for high-resolution time-of-flight or Orbitrap systems — identity is confirmed.

What ESI-MS measures

ESI produces multiply-charged ions because peptides have multiple ionizable sites — basic residues and the N-terminus. A 30-residue peptide of theoretical mass 3,200 Da typically appears as ions at m/z corresponding to charge states +2, +3, +4 — for example, m/z 1,601, 1,067, and 801 for the same peptide. The mass spectrometer software deconvolutes the multiply-charged signal back to a single molecular weight value.

A clean ESI-MS spectrum shows a series of charge-state peaks at the predicted m/z values, all reconvolving to a single molecular weight matching the theoretical. Anomalies — peaks at unexpected m/z, doublets indicating mass-shifted variants, broad peaks indicating heterogeneity — are interpretable signals about what else is in the sample. The visual diagnostic is its own skill, walked through in what a clean mass spec spectrum looks like.

What MS cannot tell you

• MS does not quantify purity directly. Two peptides with different sequences can have the same molecular weight (isobaric variants); MS alone cannot distinguish them quantitatively without tandem MS/MS sequencing.
• MS does not detect non-ionizing contaminants. Counter-ions, salts, and small organic impurities may not ionize well under standard ESI and so are not represented in the spectrum at proportional intensity.
• MS reports relative ion abundance, not absolute concentration. Peak intensity in a spectrum is not directly proportional to the amount of compound in the sample — different compounds ionize with different efficiencies.

These are the reasons MS is paired with HPLC rather than used alone. MS confirms what the dominant compound is; HPLC quantifies how dominant it is.

How does HPLC quantify purity?

High-Performance Liquid Chromatography separates compounds in a sample by their differential interaction with a column packing material, and reports each compound as a peak on a chromatogram. The proportion of the total chromatogram area that the target peak represents is the purity percentage. For peptides, the dominant variant is reverse-phase HPLC (RP-HPLC) on a C18 column. The mechanism is well-characterized; the math is simple area-normalized peak integration; and the result is reproducible across labs when the method is documented per USP <621>.

The deeper mechanics — what the percentages actually mean, how peaks are integrated, and why ≥99% is the working threshold — are covered in the dedicated HPLC purity cornerstone.

Why HPLC is the purity method, not MS

HPLC physically separates compounds in time before measuring them. Two co-eluting compounds appear as one peak (a known limitation, but resolvable with method development), but most synthesis byproducts have different physical interactions with the column and separate into their own peaks. Each peak's area is a direct, quantifiable measurement of how much of that compound is in the sample.

Mass spectrometry, by contrast, is not a separation method. It analyzes a mixture wholesale, and impurities present in the mixture distort the signal in non-linear ways. MS works as a confirmation tool on a sample that HPLC has already characterized — the two methods together are how a complete picture is built.

How does the LAL endotoxin assay actually work?

Bacterial endotoxin — specifically lipopolysaccharide (LPS) from the outer membrane of Gram-negative bacteria — is a contaminant that neither HPLC nor mass spec is designed to detect. Endotoxin can be present at biologically meaningful concentrations and remain entirely invisible to the purity and identity methods. It requires its own assay.

The standard method is the Limulus Amebocyte Lysate (LAL) assay, codified in USP <85>. The test exploits the blood-clotting cascade of the horseshoe crab (Limulus polyphemus) — amebocytes from the crab's blood produce a coagulation cascade in the presence of endotoxin, and the assay quantifies endotoxin by measuring the cascade's activity. The result is reported in endotoxin units per milligram (EU/mg), a unit that ties to a defined potency standard so values can be compared across labs.

LAL variants — gel-clot, chromogenic, turbidimetric

LAL is performed in three formats, all measuring the same coagulation chemistry but reading the result differently:

• Gel-clot LAL is the simplest format — the assay is observed visually for clot formation. Pass/fail at a defined threshold. Inexpensive but binary.
• Chromogenic LAL uses a synthetic substrate that releases a colored compound as the coagulation cascade activates. Quantitative across a range of endotoxin concentrations.
• Turbidimetric LAL measures the optical turbidity change as the gel forms. Quantitative, common in automated lab equipment.

A reputable COA specifies which variant was used. The numeric result has the same units regardless of variant, but knowing the format helps interpret precision: a chromogenic result reported to 0.05 EU/mg has more analytical precision than a gel-clot pass/fail at the same threshold.

rFC — the recombinant alternative

Recombinant Factor C (rFC) is an alternative endotoxin detection method that uses a recombinant form of the active enzyme from the LAL cascade, eliminating the need to source the assay from horseshoe crab blood. It produces equivalent endotoxin readings, with the advantage of being supply-chain-stable and animal-free. USP <86> covers rFC methodology specifically. Adoption is growing in the analytical-lab industry, and a COA may report endotoxin via either method, with the numeric value treated as interchangeable. The deeper comparison of LAL and rFC goes into the differences for application contexts that care.

What endotoxin testing cannot tell you

• LAL detects only bacterial endotoxin. Other contaminants — fungal beta-glucans, viral particles, host-cell proteins from biological starting materials — are not detected by LAL.
• LAL has a sensitivity range. Both very low and very high endotoxin levels can fall outside the assay's reliable readings; results below the detection limit are reported as "<X EU/mg" rather than as zero.
• LAL does not screen for sterility. "Endotoxin clear" does not mean "microbiologically sterile." Sterility testing is a separate procedure (USP <71>) that culture-tests for viable organisms.

Why does batch release require all three?

A research peptide batch is released for shipment when the three independent results align: identity confirmed (MS), purity above threshold (HPLC ≥99% in Nexara's case), and endotoxin within acceptance criteria (LAL or rFC). Each result independently has to pass — none of them is a substitute for any other.

Skipping any one of the three creates a known blind spot:

• Skip MS: the batch could be 99% pure of the wrong compound. The vendor knows what they synthesized, but the COA verifies nothing without identity confirmation.
• Skip HPLC: the batch could be the right compound at 90% purity, with 10% byproducts. MS alone wouldn't flag this because the dominant ion in the spectrum is still the target.
• Skip endotoxin: the batch could be 99.9% pure target peptide that triggers immunological responses in research applications because of contaminating LPS that no amount of purity testing would detect.

Reputable suppliers test all three. Less reputable suppliers test one or two and present the result as if it were a complete characterization. Reading a COA is partly the skill of noticing what test is missing — the field-by-field walkthrough covers where each result should appear on the document.

Where do ancillary tests fit?

Beyond the three core methods, a complete COA may include ancillary observations that the core trio doesn't cover:

• Water content by Karl Fischer titration — residual moisture from the lyophilization process. High water content is a stability concern. Typically reported as a percentage.
• Counter-ion content for peptides synthesized as TFA or acetate salts — the salt form affects net molecular weight calculations downstream.
• Appearance — visual inspection. "White to off-white powder" is the standard descriptor for lyophilized peptides; deviations are flags.
• pH of reconstituted solution at a defined concentration — informs the buffer compatibility of the peptide.
• Solubility characterization in defined solvent systems — informs reconstitution practice.

These are not substitutes for the core three. They are routine checks that catch issues the core methods aren't designed to catch.

How does Nexara structure testing?

Every research peptide product is tested against all three core methods at an independent laboratory before it ships. The results appear on the batch's Certificate of Analysis, which is provided on request. Bacteriostatic Water reconstitution supplies follow a different standard — they are USP-grade sterility, not peptide purity testing — because they are aqueous reconstitution materials, not active compounds. The full operational picture lives in our quality standards, and what we deliberately do not publish (reconstitution calculators, dose math) is documented in research compliance.

On accreditation: the laboratory partner's ISO/IEC 17025 status is named on the issued COA. Vendor-side marketing pages do not name the partner because lab partnerships can change between batches; the COA is the authoritative record of who tested what.

Sources and further reading

• USP <85> Bacterial Endotoxins Test — the canonical pharmacopeial standard for LAL methodology, including all three reading variants (gel-clot, chromogenic, turbidimetric).
• USP <86> Bacterial Endotoxins Test Using Recombinant Reagents — methodology for rFC-based endotoxin detection.
• USP <621> Chromatography — system suitability and reporting standards for HPLC purity assays.
• USP <736> Mass Spectrometry — pharmacopeial standard for the use of mass spectrometry in compendial testing.
• ISO/IEC 17025:2017 — the accreditation framework for analytical labs.
• FDA Guidance for Industry: Pyrogen and Endotoxins Testing — Questions and Answers — regulatory context on LAL methodology and acceptance criteria.
• Wuhrer & Deelder — Mass Spectrometry of Peptides and Proteins (Methods in Molecular Biology) — methodological reference for peptide-specific MS analysis.